Latest news with #SPIMACO
Argaam
27-07-2025
- Business
- Argaam
SPIMACO launches oncology, high-potent drug plant
Saudi Pharmaceutical Industries and Medical Appliances Corp. (SPIMACO) inaugurated its oncology and high potent drugs plant at a total value of SAR 272 million. In a statement to Tadawul today, July 27, SPIMACO said the plant boasts an annual production capacity exceeding 275 million therapeutic units. Incorporating the latest technologies, the new facility adopts the highest international standards in pharmaceutical manufacturing, ensuring operational efficiency, personnel safety, and environmental sustainability. As all technical, regulatory, and operational requirements were completed, the plant will produce the first commercial batches this month, SPIMACO stated.
Makkah Newspaper
24-07-2025
- Health
- Makkah Newspaper
Saudi Arabia's Pharma Leap to Global Leadership
Dear reader, over the past decade, Saudi Arabia has undertakenan ambitious overhaul of its healthcare and life sciences landscape. Guided by Vision 2030, the Kingdom is positioning itself as a knowledge‑driven economy with a robust, self‑reliant pharmaceutical sector. Recent data from IQVIA andEuromonitor highlight progress on several key fronts, including market expansion, manufacturing capacity, hospital infrastructure, and tender market dynamics. Here's a closer look at the numbers and why they matter. Across the broader Middle East and Africa (MEA) region, pharmaceutical sales increased from USD 24.2 billion in 2020 to USD 29.5 billion in 2023 and are projected to surpass USD 32.6 billion in 2024, representing a cumulative growth of approximately 35% over the four years. Saudi Arabia is the primary growth driver, with the Kingdom's share increasing from USD 8.7 billion to USD 11.6 billion, underscoring strong domestic demand and rising purchasing power. The UAE, SouthAfrica, and Algeria follow closely, while smaller markets, such as Lebanon, Jordan, and Kuwait, are expanding steadily from a lower base. Dear reader, Zooming in on Saudi Arabia's five largest therapy areas, combined sales rose from about USD 3.8 billion in 2019 to a forecasted USD 5.6 billion by 2026 (a 6.5 % compound annual growth rate). General medicines alone are expected to exceed USD 2.8 billion by 2026, followed by consumer health products at roughly USD 750 million, driven by trends in preventive care and wellness. Dermatology, digestive health, and ophthalmology remain smaller niches, but they are growing at 5–7% per year as urban lifestyles increase demand for allergy treatments and chronic disease medications. Government tenders remain the backbone of public procurement, valued at approximately USD 5.6 billion. Two multinationals, Hikma and Sanofi, lead with 9 % share each. Local champions SPIMACO (8%) and Tabuk Pharmaceuticals (7%) rank closely behind, while Pfizer, Novo Nordisk, and Novartis each hold 5–6%. At the other end of the scale, Jamejoom Pharma captures just 1 %, signaling headroom for domestic firms to ramp up portfolios tailored to tender specifications. Dear reader, domestic production is spreading across a broader base of players (over 2,100 registered items). Pharmaceutical Solution Industries (PSI) tops the chart with 21% of national output, followed by Tabuk (18%) and SPIMACO (15%).Jamejoom, Riyadh Pharma, and Jazeera Pharma each command roughly 8–9 %, while a long tail of other manufacturers together accounts for 20 %. The distribution highlights Ministry of Industry incentives to increase local content, promote innovation, and enhance exports, particularly following the launch of the National Biotechnology Strategy. Dear reader, several forces are converging: sweeping healthcarefinancing reforms, incentives for local manufacturing that deepen supply chain resilience, a welcoming stance toward foreign direct investment, and rapid digital adoption, from telemedicine to e-prescriptions. Although rising healthcare costs and chronic disease burdens pose challenges, current indicators suggest an ample runway for both local and international drugmakers, especially in biologics, targeted therapies, and self-care products. Saudi Arabia is charting a course to become the region's premier hub for pharmaceutical innovation and high‑quality healthcare services. With a sizable domestic market, expanding infrastructure, and policies favorable to private enterprise, the Kingdom could, by the end of the decade, rank among the most attractive healthcare markets in the broader Middle East and North Africa. In short, the 'Saudi pharma leap' is no longer aspirational rhetoric; it is unfolding on the ground. Continued execution will be vital, but the trajectory points to a future where Saudi Arabia not only meets local medical needs more efficiently but also exports health solutions to the world.
Yahoo
13-05-2025
- Business
- Yahoo
Saudi Arabia Contract Manufacturing Organizations (CMO) Market Trends, Competition, Forecasts & Opportunities, 2020-2024 & 2025-2030
Saudi Arabia's Contract Manufacturing Organizations (CMOs) market is set to grow from USD 29.68M in 2024 to USD 48.80M by 2030 at a CAGR of 8.60%. Vision 2030 and increased pharma investments boost demand. Key challenges include a limited skilled workforce. Major players: SAJAPHCO, SPIMACO, and Jamjoom Pharmaceuticals. Saudi Arabian Contract Manufacturing Organizations Market Dublin, May 13, 2025 (GLOBE NEWSWIRE) -- The "Saudi Arabia Contract Manufacturing Organizations Market, Region, Competition, Forecast & Opportunities, 2020-2030F" has been added to offering. The Saudi Arabia Contract Manufacturing Organizations (CMO) market, valued at USD 29.68 million in 2024, is projected to reach USD 48.80 million by 2030, expanding at a CAGR of 8.60%. CMOs, also known as Contract Development and Manufacturing Organizations (CDMOs), play a crucial role in supporting pharmaceutical, biotechnology, and life sciences industries by offering comprehensive manufacturing and development services, including active pharmaceutical ingredients, finished products, sterile products, biologics, and vaccines. Saudi Arabia's burgeoning pharmaceutical and biotech sectors are witnessing a significant boost from increased government investment and regulatory support under Vision 2030. This strategic initiative enhances healthcare self-sufficiency, escalating healthcare expenditures, and offers incentives for foreign investment. These factors are transforming Saudi Arabia into a regional hub for pharmaceutical manufacturing and development, with CMOs acting as pivotal partners, enabling firms to scale production, enhance efficiency, and access broader markets. Key Market Drivers Vision 2030 and associated government initiatives are critical drivers of the CMO market's growth by promoting economic diversification and bolstering healthcare and pharmaceutical sectors. The government encourages localization, requiring multinational firms to establish local operations or collaborate with domestic CMOs, enhancing demand for these services. CMOs facilitate cost-effective localization, supported by sector-specific partnerships and investments in infrastructure, aligning with national objectives for sustainable growth. Key Market Challenges The limited skilled workforce in pharmaceutical and biotechnology manufacturing presents challenges. Expertise in bioprocessing, sterile production, and regulatory compliance is scarce, pushing companies to recruit internationally, complicating operations and increasing costs. Companies must invest in training and academic partnerships to cultivate local talent, overcoming growth constraints and maintaining competitive standards in quality assurance and compliance. Key Market Trends Outsourcing is a rising trend, driven by pharmaceutical companies focusing on core activities like research and commercialization. CMOs provide specialized manufacturing services, ensuring cost efficiency and scalability. They offer expertise in sterile processing and complex formulations, allowing companies to manage production volumes and supply chain risks while meeting regulatory standards. This outsourcing trend promotes innovation and operational agility, critical for firms seeking a competitive edge and streamlined global market access. Key Market Players Saudi Arabian Japanese Pharmaceutical Company (SAJAPHCO) AJA Pharmaceutical Industries Company LTD Saudi Pharmaceutical Industries & Medical Appliances Corporation (SPIMACO) Jamjoom Pharmaceuticals Co. Banjara Holdings Batterjee Pharmaceutical Report Scope By Type: Active Pharmaceutical Ingredients (API) Manufacturing Finished Dosage Formulation (FDF) Development & Manufacturing Secondary Packaging By End User: Big Pharmaceuticals Small and Mid-Size Pharmaceuticals Generic Pharmaceutical Companies Others By Region: Eastern Western Northern & Central Southern Key Attributes: Report Attribute Details No. of Pages 85 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $29.68 Million Forecasted Market Value (USD) by 2030 $48.8 Million Compound Annual Growth Rate 8.6% Regions Covered Saudi Arabia For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Saudi Arabian Contract Manufacturing Organizations Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Zawya
13-05-2025
- Business
- Zawya
Saudi: SPIMACO's net profits leap 90% in Q1-25
Riyadh – Saudi Pharmaceutical Industries and Medical Appliances Corporation (SPIMACO) logged net profits worth SAR 75.10 million in the first quarter (Q1) of 2025. The generated earnings were higher by 90.12% year-on-year (YoY) than SAR 39.50 million, according to the financial results. Revenues grew by 1.87% to SAR 484.80 million in Q1-25 from SAR 475.90 million in Q1-24. The earnings per share (EPS) hit SAR 0.59 as of 31 March 2025, higher than SAR 0.30 a year earlier. Quarterly, the company turned profitable in Q1-25 when compared to net losses of SAR 35.90 million in Q4-24. The revenues climbed by 25.53% from SAR 386.20 million. Last month, SPIMACO named Khalid Abdulrahman Alqwaiz and Ahmad Hamdan Aljedai as the board's Chairman and Vice Chairman, respectively. Source: Mubasher
